A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis.
This study was aimed at evaluating the immunogenicity of a vaccine composed of killed Leishmania amazonensis promastigotes using several different protocols in a randomized, double-blind and controlled trial design in order to select one of them for further efficacy trials. One hundred and fourteen leishmanin skin test (LST)-negative healthy volunteers were allocated into eight groups that received either two or three deep intramuscular injections of vaccine at doses of 180, 360 and 540 microg or similar injections of placebo. Cell-mediated immune responses were evaluated before and after vaccination by means of LST as well as proliferative responses and cytokine production in Leishmania antigen-stimulated peripheral blood mononuclear cell cultures. The majority of the subjects who actually received vaccine converted to positive LST (89.5%). On the other hand, none of the subjects who received placebo converted to positive LST. Proliferative responses and production of interferon-gamma and interleukin-2 were significantly higher after vaccination than before vaccination in all groups, including those that received placebo. The dose of 360 microg provided the highest LST conversion rate (100%), as well as the greatest increase in interferon-gamma and interleukin-2 production after vaccination.
De Luca
P M
PM
Departamento de Imunologia, Instituto Oswaldo Cruz, FIOCRUZ, Av. Brasil 4365-Manguinhos, CP 926, CEP 21045-900, Rio de Janeiro RJ, Brazil.
Mayrink
W
W
Pinto
J A
JA
Coutinho
S G
SG
Santiago
M A
MA
Toledo
V P
VP
Costa
C A
CA
Genaro
O
O
Reis
A B
AB
Mendonça
S C
SC
D000293:Adolescent; D000328:Adult; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007891:Leishmania / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology* / Q000517:prevention & control*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology*; D012882:Skin Tests; D014611:Vaccination
D000953:Antigens, Protozoan; D016207:Cytokines; D016052:Protozoan Vaccines; C032127:leishmanin